Methods of ultrasound treatment using gas or gaseous precursor-filled compositions

• US 6,716,412 B2
• Filed: 03/21/2001
• Issued: 04/06/2004
• Est. Priority Date: 09/15/1997
• Status: Expired due to Term

• Current Assignee: Cerevast Medical, Inc.
• Original Assignee: Imarx Therapeutics, Inc. (Sycamore Entertainment Group, Inc.)
• Inventors: Unger, Evan C.
• Primary Examiner(s): Travers, Russell
• Assistant Examiner(s): SHARAREH, SHAHNAM J
• Application Number:
  US09/813,484
• Publication Number:
  US 20010031243A1
• Time in Patent Office: 1,112 Days
• Field of Search: 424/9.52, 424/9--, 424/450, 604/21, 604/52, 514/44, 660/437
• US Class Current: 424/9.52
• CPC Class Codes: A61K 41/0028 Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
• CPC Class Codes: A61K 49/227 Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric

Abstract

The present invention describes, among other things, the surprising discovery that gaseous precursor filled compositions are profoundly more effective as acoustically active contrast agents when they are thermally preactivated to temperatures at or above the boiling point of the instilled gaseous precursor prior to their in vivo administration to a patient. Further optimization of contrast enhancement is achieved by administering the gaseous precursor filled compositions to a patient as an infusion. Enhanced effectiveness is also achieved for ultrasound mediated targeting and drug delivery.

Claims

1. A method for lysing an intravascular blood clot in the brain of a patient, said method comprising:

(i) heating a composition comprising lipid vesicles encapsulating a gaseous precursor to a temperature at or above the boiling point of the gaseous precursor, wherein said gaseous precursor is a fluorinated compound, said lipid vesicles comprise at least one phosphatidylcholine, at least one phosphatidylethanolamine, and at least one phosphatidic acid, wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoyl-phosphatidylcholine;

said phosphatidylethanolamine is selected from the group consisting of dipalmitoylphosphatidylethanolamine, dioleoyl-phosphatidylethanolamine, and N-succinyl-dioleoyl-phosphatidylethanolamine; and

said phosphatidic acid is dipalmatoylphosphatidic acid, (ii) administering said composition to a patient, and (iii) applying ultrasonic energy to the brain of the patient in an amount sufficient to cavitate or rupture at least a portion of said vesicles.

2. A method according to claim 1, wherein said vesicle composition is administered as an intravascular infusion.

3. A method according to claim 2, wherein said vesicle composition is administered as an intra-arterial infusion.

4. A method according to claim 1, wherein said gas or gaseous precursor comprises a perfluorocarbon.

5. A method according to claim 4, wherein said perfluorocarbon is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane and perfluorocyclohexane.

6. A method according to claim 5, wherein said perfluorocarbon is selected from the group consisting of perfluoropropane, perfluorocyclopropane, perfluorobutane, and perfluorocyclobutane.

7. A method according to claim 1 wherein said vesicles further comprise a hydrophilic polymer.

8. A method according to claim 7, wherein said hydrophilic polymer comprises polyethylene glycol.

9. A method according to claim 1, wherein said vesicles further comprise a targeting ligand.

10. A method according to claim 9, wherein said targeting ligand is covalently bound to said vesicles via a hydrophilic polymer linking group.

11. A method according to claim 9, wherein said targeting ligand targets cells or receptors selected from the group consisting of endothelial cells and the glycoprotein GPIIbIIIa receptor.

12. A method according to claim 11, wherein said targeting ligand is selected from the group consisting of proteins, peptides, saccharides, steroids, steroid analogs, bioactive agents and genetic material.

13. A method according to claim 12, wherein said targeting ligand is selected from the group consisting of proteins, peptides and saccharides.

14. A method according to claim 13, wherein said targeting ligand is selected from the group consisting of proteins and peptides.

15. A method according to claim 14, wherein said targeting ligand comprises a peptide.

16. A method according to claim 15, wherein said peptide comprises the sequence Arg-Gly-Asp.

17. A method according to claim 1, wherein said ultrasound is applied through a surgically created window in the skull.

18. A method according to claim 1, wherein said ultrasound is applied in a pulsed and focused mode.

19. A method according to claim 1, wherein said vesicles further comprise a bioactive agent.

20. A method according to claim 18, wherein said bioactive agent is selected from the group consisting of anti-coagulation agents, circulatory agents, anti-inflammatories, corticosteroids, tissue plasminogen activator, streptokinase, and urokinase.

21. A method according to claim 1 further comprising scanning the patient with diagnostic imaging to identify the location of said blood clot in the brain.

22. A method according to claim 21, wherein said scanning is performed after initiating administration of said vesicle composition.

23. A method according to claim 21, wherein said diagnostic imaging comprises nuclear medicine imaging.

24. A method according to claim 21, wherein said diagnostic imaging comprises ultrasound imaging.

25. A method according to claim 15, wherein said peptide has the sequene Lys-Gln-Ala-Gly-Asp-Val.